Immunosuppressive Therapy for Transplant Market Growth (2022-2030) | Industry Share, Size, Trends and Global Forecast Report
Growth Plus Reports
Updated 7 min read
Growth Plus Reports
Newark, New Castle, USA, March 15, 2023 (GLOBE NEWSWIRE) -- According to the latest report published by Growth Plus Reports, the global Immunosuppressive Therapy for Transplant Market is expected to clock US$ 10.78 billion by 2030 and to grow at a CAGR of 4.56% during the forecast period. Owing to the increasing incidence of chronic diseases and upsurges in the number of transplant donors, states Growth Plus Reports.
Immunosuppressive therapy for transplant is commonly a multidrug strategy involving medications with various modes of action. It is employed to suppress the activity of the immune system, restricting transplant rejection. Antibody agents or stronger dosages of drugs used for maintenance therapy can be utilized as induction therapy. The initial medicine regimen frequently comprises calcineurin inhibitors, antiproliferative drugs, and corticosteroids. Different withdrawal procedures are employed in practice due to the possibility of nephrotoxicity with the use of calcineurin inhibitors and other chronic diseases due to the continued use of corticosteroids. Antimicrobial medications are recommended to give prophylaxis against specific viral, fungal, and bacterial infections. Depending on patient-specific characteristics and conditions, different concomitant drugs are included in the treatments for patients who have undergone transplantation.
Immunosuppressive Therapy for Transplant Market Scope
Report Attribute
Details
Market size value in 2021
US$ 7.54 billion
Revenue forecast in 2030
US$ 10.78 billion
Growth Rate
CAGR of 4.56% from 2022 to 2030
Base year for estimation
2021
Forecast period
2022-2030
Historical Year
2020
Segments covered
Drug Class, Transplant Type, and Region
Regional scope
North America, Europe, Asia Pacific, and the Rest of the World (ROW)
Market Driver
The main driver fueling the growth of the immunosuppressive therapy for transplant market is the increased organ transplant procedures, such as kidney and liver transplants, brought on by an increase in cases of organ failure. According to the U.S. Government Information on Organ Donation and Transplantation, 36,528 transplants occurred nationwide in 2018. Moreover, according to the American Kidney Fund, there were more than 106,000 patients on the national transplant waiting list in June 2022, of whom 92,000 (or 87%) were waiting for a kidney transplant in the United States. Therefore, the market is growing significantly by the rising prevalence of organ failure in patients and the need for organ transplants.
Excerpts from ‘By Drug Class Segmentation’
Based on the drug class, the global immunosuppressive therapy for transplant market is segmented as:
Calcineurin Inhibitors
Antiproliferative Agents
Antibodies
Small Biological Agents
Others
The calcineurin inhibitor segment accounted for the largest revenue share of the global immunosuppressive therapy for transplant market in 2021. The most often used immunosuppressive treatment is calcineurin inhibition, which has a long history of use in kidney transplant patients. Corticosteroids and other immunosuppressive medications are linked to various adverse effects, including hyperlipidemia, osteoporosis, glucose intolerance, vascular disease, and hypertension. Thus, using calcineurin inhibition is frequently prescribed for patients. These drugs have suppressive effects on both humoral and cellular immune processes. These substances inhibit rejection reactions, which enhances short-term results. Although less nephrotoxic, it is linked to bone marrow suppression, slower wound healing, and hyperlipidemia.
Excerpts from ‘By Region Segmentation’
Based on the region, the global immunosuppressive therapy for transplant market is segmented into:
North America
Europe
Asia Pacific
Rest of the World
North America accounted for the largest revenue share of the global immunosuppressive therapy for transplant market in 2021. The global market in North America is driven by the growing demand for tissue and organ transplantation to treat multiple diseases. Organ transplantation has seen growth due to the rising incidence of renal disease, excessive alcohol use, and poor diet, with a large population afflicted by organ failure and chronic sickness in this region. The segment is also being boosted by the rising adoption of advanced technology, rising organ and tissue banks, and new treatment that contributes to the development of advanced therapy. Globally, there is a high demand for replacement organs, particularly for the kidney, heart, and liver. The rising population with several chronic diseases boosts the demand for alternative regenerative treatments, which drives the preference for stem cell transplantation over traditional treatments. Therefore, a substantial rise in the number of procedures is likely to increase the overall transplantation occurrence in this region.
Whereas, due to expanding stem cell research to create in-vitro tissue and organs and improving healthcare infrastructure in Asian nations like India, Thailand, the Philippines, and Indonesia, the Asia Pacific market is anticipated to grow at the highest CAGR over the forecast period.
Due to the presence of numerous major, small, and medium-sized merchants, the market is extremely competitive. The leading companies in the sector are:
Astellas Pharma Inc.
Accord Healthcare Ltd.
AbbVie Inc.
Novartis AG
Genzyme Corporation (Sanofi S.A.)
Mylan Laboratories, Inc.
GlaxoSmithKline plc.
Belcher Pharmaceutical LLC
Leo Pharma AS
Glenmark Pharmaceuticals Ltd.
TFF Pharmaceuticals LLC
TolerogenixX GmbH
Veloxis Pharmaceuticals Inc.
Dr. Reddy's Laboratories Ltd.
Panacea Biotec Ltd.
Strides Pharma Global Pte Ltd.
F. Hoffmann-La Roche AG
Table of Content
INTRODUCTION
Market Ecosystem
Timeline Under Consideration
Historical Years – 2020
Base Year – 2021
Forecast Years – 2022 to 2030
Currency Used in the Report
RESEARCH METHODOLOGY
Research Approach
Data Collection Methodology
Data Sources
Secondary Sources
Primary Sources
Market Estimation Approach
Bottom Up
Top Down
Market Forecasting Model
Limitations and Assumptions
PREMIUM INSIGHTS
Current Market Trends (COVID-19 Perspective)
Key Players & Competitive Positioning (2021)
MARKET DYNAMICS
Drivers
Restraints/Challenges
Opportunities
GLOBAL IMMUNOSUPPRESSIVE THERAPY FOR TRANSPLANT MARKET - ANALYSIS & FORECAST, BY DRUG CLASS
Global Neurometabolic Disorders MarketType (Gaucher's Disease, Fabry Disease, Pompe Disease), Route of Administration (Oral, Parenteral) – Global Outlook & Forecast 2022-2030
Mobility Scooters Marketby Type (Small, Medium), by Wheel (2 wheels, 4 Wheels), by Battery Range (Less Than 10 Miles, 10-20 Miles), by Application (Indoor & Outdoor)– Global Outlook & Forecast 2022-2030
RNAi Therapeutics Marketby Disease Type (RNA Interference, RNA Antisense), by Application (Oncology, Ocular Disorders, Respiratory Disorders), by End User (Research Institutes, Hospitals & Clinics) – Global Outlook & Forecast 2022-2030
Metastatic Breast Cancer Marketby Treatment Type (Chemotherapy, Biologic Targeted Therapy, Radiation Therapy), End User (Hospitals, Clinics) - Global Outlook & Forecast 2022-2030
Mass Spectrometry Marketby Product Type (Hybrid, Single), by Application (Pharmaceutical Analysis, Proteomics, Metabolomics), by End-user (Pharmaceutical & Biotechnology, Food & Beverage Testing) Global Outlook & Forecast 2022-2030
About Us:
Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).
Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.
We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020.
